Gilead Sciences: New Prescriptions of Hepatitis C Drugs Slow

UBS analyst Matthew Roden and team note that new prescriptions for Gilead Sciences’ hepatitis-C drugs are slowing: AP Scripts for Gilead’s Harvoni during the week ending November 21 totaled 4,366, up +21% w/w. This implies a total franchise [total prescriptions, or] TRx (i.e. Sovaldi + Harvoni) of 7,813, up + 5%, and franchise [new prescriptions, [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.